Uwe Staub - Epigenomics AG Insider

Epigenomics AG -- USA Stock  

USD 5.65  0.00  0.00%

COO and Member of Executive Board

Dr. Uwe Staub is Chief Operating Officer of Epigenomics AG since April 1, 2013. Prior to that, he served as Senior Vice President Research and Development Manufacturing of the Company from November 1, 2008. He was also granted procura and will take over the responsibility for medical affairs and customer support of the Company. Before joining the Company, Dr. Staub worked 14 years in the IVD industry for Abbott Diagnostics, Digene and Qiagen and gained experience in Operations, Quality and Regulatory Affairs as well as Product Development. He studied Biology at the JuliusMaximiliansUniversitaet Wuerzburg, Germany, and earned his Ph.D degree in Biochemistry and Human Genetics.
  COO Since 2013  Ph.D    
49 30 243 450  http://www.epigenomics.com

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Berlin, and employs 43 people.

Did you try this?

Run Money Managers Now
   

Money Managers

Screen money managers from public funds and ETFs managed around the world
Hide  View All  Next  Launch Money Managers
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Epigenomics AG to your portfolio

Top Management

Epigenomics AG Leadership Team
Albert Weber, SVP
Antje Zeise, Executive
Guenther Reiter, Executive
Gregory Hamilton, CEO, MBA
Ann Kessler, Executive
Heino Prondzynski, Chairman
Thomas Taapken, CEO
Annett Dietrich, Executive
Noel Doheny, CEO
Nicola HennebergBusse, President
Uwe Staub, COO, Ph.D
Peter Vogt, Executive

Stock Performance

Epigenomics AG Performance Indicators
Return On Equity(122.69) %
Return On Asset(44.29) %
Operating Margin(418.57) %
Current Valuation104.35 M
Price to Earning(8.47) times
Price to Book11.08 times
Price to Sales39.6 times
Revenue3.16 M
Gross Profit1000 K
EBITDA(13.22 M)